Director of API retires

By Dylan Bushell-Embling
Thursday, 10 July, 2008

A director of Australian Pharmaceutical Industries [ASX: API], Barry Frost, announced his retirement today.

Frost has served on the company's board since 1993, and has been deputy chairman since 2001. His resignation will be effective July 31.

API, which markets and distributes prescription and over-the-counter medications, has announced that it is currently looking for replacement for the position.

Researchers genetically engineer snake antivenom

An international team of researchers has used genetic engineering to create so-called...

Common medications linked to adverse breast cancer outcomes

An international study has found concerning evidence about the impact of a range of common...

Saliva-based biosensor could improve heart failure detection

Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...

Content from other channels on our network

ARC announces $34m in collaborative research funding

Brisbane biomanufacturing hub signs its first tenant

Carbon280 seeks further funding for Hydrilyte technology

Highly precise and safe control of hydrogen testing

Victoria supporting a new mRNA manufacturing facility

Condensate and Cooling Water Monitoring and Aromatics Detection

Deal to create graphene-based carbon paste used in solar

Net zero or 1.2 million homes: trade-off or win-win?

Mining waste provides strong boost to concrete construction

Alta project makes existing diesel trains electric

PEAL Is Here: Why Front-End Allergen Control Matters More Than Ever

Handmade Food + High-Growth Systems: How Fishbowl scaled up Adelia's Operations

The future of food under weight-loss regimes

Tetra Pak launches technology to help make factories AI-ready

Food industry members of Australia's National Food Council